{
    "clinical_study": {
        "@rank": "95857", 
        "arm_group": {
            "arm_group_label": "Open-Label Lorcaserin (BELVIQ)", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the PK properties, tolerability, and safety of\n      lorcaserin HCL (BELVIQ) in obese adolescent subjects between the ages of 12 to 17 years old"
        }, 
        "brief_title": "Single Dose Study to Determine the Safety, Tolerability, and Pharmacokinetic Properties of Lorcaserin Hydrochloride (BELVIQ) in Obese Adolescents From 12 to 17 Years of Age", 
        "condition": "Pharmacokinetics in Obese Adolescents", 
        "condition_browse": {
            "mesh_term": "Obesity"
        }, 
        "detailed_description": {
            "textblock": "The purpose is to:\n\n        1. Assess the single-dose pharmacokinetic (PK) parameters of lorcaserin and a primary\n           metabolites (M1 and M5) in obese adolescent subjects ages 12-17 (inclusive)\n\n        2. Assess the safety and tolerability of a single oral dose of lorcaserin in obese\n           adolescent subjects ages 12-17 (inclusive)"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Adolescent subjects aged 12 to 17 years, inclusive at screening\n\n          2. a. Eligible female subjects who are sexually active will be:\n\n               -  non-pregnant\n\n               -  non-lactating\n\n               -  agree to continue to use an accepted method of birth control for at least 1\n                  month after study medication administration\n\n          3. BMI \u2265 95th percentile for age and gender, but \u2264 44 kg/m21\n\n          4. Considered to be in stable health in the opinion of the Investigator.\n\n          5. Parent or guardian who can sign written informed consent and subject willing to sign\n             assent\n\n        Exclusion Criteria:\n\n          1. Clinically significant new illness in the 1 month before screening and any time prior\n             to randomization\n\n          2. Significant renal or hepatic disease\n\n          3. Secondary (chromosomal, endocrine, or metabolic) causes of obesity\n\n          4. Use of medications other than hormonal contraceptives and acetaminophen\n\n          5. Use of  drugs with serotonergic activity within 1 month before screening\n\n          6. Recent treatment with over-the-counter weight loss products or appetite suppressants,\n             or within 3 months of screening and any time prior to randomization with a\n             prescription weight loss drug or lipid dissolving injections or ongoing psychotherapy\n             for weight loss outside of this trial\n\n          7. Recent history of alcohol, tobacco, or recreational drug/solvent use\n\n          8. Any history of major depression, anxiety, bipolar disorder, schizophrenia, or Axis II\n             psychiatric disease requiring treatment with prescription medication within six\n             months prior to screening"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "17 Years", 
            "minimum_age": "12 Years"
        }, 
        "enrollment": {
            "#text": "8", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 23, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02022956", 
            "org_study_id": "APD356-025"
        }, 
        "intervention": {
            "arm_group_label": "Open-Label Lorcaserin (BELVIQ)", 
            "intervention_name": "Lorcaserin", 
            "intervention_type": "Drug", 
            "other_name": "BELVIQ"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "March 28, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Philadelphia", 
                        "country": "United States", 
                        "state": "Pennsylvania", 
                        "zip": "19104"
                    }, 
                    "name": "Children's Hospital of Philadelphia"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "San Antonio", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "78217"
                    }, 
                    "name": "Worlwide Clinical Trials"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "An Open-label, Single-dose Study to Assess the Safety, Tolerability and Pharmacokinetic Properties of BELVIQ in Obese Adolescent Subjects Ages 12-17 (Inclusive)", 
        "overall_official": {
            "affiliation": "Arena Pharmaceuticals", 
            "last_name": "Joanne Quan, MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "December 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Assess the single-dose pharmacokinetic (PK) parameters of lorcaserin and a primary metabolites (M1 and M5) in obese adolescent subjects ages 12-17 (inclusive)", 
            "time_frame": "45 min pre-dose and at 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48, 72, and 96 hours post-dose"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02022956"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Arena Pharmaceuticals", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Arena Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2013", 
        "study_design": "Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}